Search Results

PacBio today announced a collaboration with the University of Tokyo , Graduate School of Medicine to study the use of long-read sequencing and novel bioinformatics methods in the hopes of better understanding the genetic causes of certain rare diseases in individuals and cohorts within the Japanese population.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Everest Medicines’ (HKEX 1952.HK, “Everest”, or the “Company”) partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) presented new biomarker and subgroup analyses from Nefecon®'s Phase 3 NefIgArd study in both posters and oral presentations at the 17th International Symposium on IgA Nephropathy held in Tokyo, Japan.

The University of Tokyo and Astellas Pharma Inc. entered the second phase of their collaboration for co-creating innovative new medicines and medical solutions, called the Astellas Alliance Acceleration Program.

MediciNova, Inc., today announced that it will initiate a comprehensive research collaboration with Juntendo University, School of Medicine (2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan) to evaluate the mechanism of the action of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting.

B dot Medical Inc. has signed a memorandum of understanding with Edogawa Hospital in Japan for the installation of the company’s first practical ultra-compact proton therapy system, which means the first proton therapy facility to be established in Tokyo.